IP Verse

Substituted Tetrahydrofurans As Modulators Of Sodium Channels - EP4069691B1

PatentPatent Analysis

EP4069691

VERTEX PHARMACEUTICALS INCORPORATED
Application Number
EP20825397A
Filing Date
Dec 4, 2020
Status
Granted And Under Opposition
Aug 15, 2024
Grant Date
Sep 18, 2024
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP2464337B2
EP2914248B2
EP3925607B1

Bibliography

The patent EP4069691B1 was granted to Vertex Pharmaceuticals Incorporated on Sep 18, 2024 following the initial filing on Dec 4, 2020 under the application number EP20825397A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BARDEHLE PAGENBERGJun 17, 2025ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents